Amgen executive exercises options, sells 3,890 shares

Amgen Inc. executive Derek Miller, SVP of Human Resources, exercised stock options for a total of 3,890 shares of common stock on August 6, 2026, at strike prices of $162.60 and $177.46 per share.

Rhea-AI Filing Summary

Amgen Inc. executive Derek Miller, SVP of Human Resources, exercised stock options for a total of 3,890 shares of common stock on August 6, 2026, at strike prices of $162.60 and $177.46 per share. He then sold 3,890 common shares at a weighted-average price of $402.5444 per share in open market or private transactions. Footnotes state these sales include shares used to cover the option exercise price and required withholding taxes, and separately describe 117 dividend equivalents credited to unvested restricted stock units under Amgen's equity incentive plan.

Insider Trade Summary

Exercise and Sale: 3,890 shares ($906K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Miller Derek

Role SVP, Human Resources

Sold 3,890 shs ($1.57M)

Approx. gross sale proceeds $1.57M

Approx. exercise cost $660K

Approx. pre-tax spread $906K

Type	Security	Shares	Price	Value
Exercise	Nqso (Right to Buy)	2,069	$0.00	$0.00
Exercise	Nqso (Right to Buy)	1,821	$0.00	$0.00
Exercise	Common Stock	2,069	$162.60	$336K
Sale	Common Stock F1, F2	2,069	$402.5444	$833K
Exercise	Common Stock	1,821	$177.46	$323K
Sale	Common Stock F1, F2, F3	1,821	$402.5444	$733K

Holdings After Transaction: Nqso (Right to Buy) — 0 contracts (Direct); Common Stock — 12,462 shares (Direct)

Footnotes (3)

1. F1. Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.
2. F2. The price reported is an average price of $402.5444 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
3. F3. These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

Options Exercised: 3,890 shares Exercise Price 1: $162.6000 per share Exercise Price 2: $177.4600 per share +3 more

6 metrics

Options Exercised 3,890 shares Total NQSO shares exercised on 2026-08-06

Exercise Price 1 $162.6000 per share Strike price for 2,069 NQSO shares exercised

Exercise Price 2 $177.4600 per share Strike price for 1,821 NQSO shares exercised

Shares Sold 3,890 shares Common stock sold following option exercises on 2026-08-06

Average Sale Price $402.5444 per share Weighted-average price for the reported sales

Dividend Equivalents 117 DEs credited to unvested RSUs under Amgen’s 2009 Equity Incentive Plan

Key Terms

Nqso (Right to Buy), Dividend Equivalents (DEs), Restricted Stock Units, qualifying dividend reinvestment plan

4 terms

Nqso (Right to Buy) financial

"security_title: Nqso (Right to Buy) with underlying Amgen common stock"

Dividend Equivalents (DEs) financial

"These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. plan"

Restricted Stock Units financial

"DEs are credited to the reporting person's unvested Restricted Stock Units and paid in shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

qualifying dividend reinvestment plan financial

"DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Derek Miller report for AMGN on August 6, 2026?

Derek Miller reported exercising stock options for 3,890 Amgen shares and selling the same 3,890 common shares on August 6, 2026. The sales followed option exercises at lower strike prices and were executed at an average price of $402.5444 per share.

How many Amgen (AMGN) stock options did Derek Miller exercise and at what strike prices?

He exercised nonqualified stock options covering 2,069 shares at a strike price of $162.60 and another 1,821 shares at $177.46. These option exercises converted the derivatives into equivalent shares of Amgen common stock before the reported sales.

At what price did Derek Miller sell his Amgen (AMGN) shares on August 6, 2026?

He sold 3,890 Amgen common shares at a weighted-average price of $402.5444 per share. A footnote explains this is an average across multiple trades, with full trade-by-trade pricing information available to the SEC, the issuer, or its security holders upon request.

Did Derek Miller’s AMGN share sales include shares used to pay option costs or taxes?

Yes. A footnote states the reported sales include shares sold to cover the option exercise price and required withholding taxes tied to the exercise of expiring options. This means part of the transaction satisfied obligations arising from the option exercises.

What are the 117 Dividend Equivalents mentioned in Derek Miller’s AMGN filing?

The filing notes that certain reported shares include 117 Dividend Equivalents (DEs) granted under Amgen’s 2009 Equity Incentive Plan. These DEs are credited to unvested restricted stock units and are paid out in Amgen common stock on a one-to-one basis as the RSUs vest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 06:47 PM Accepted by SEC EDGAR 08/07/2026 - 06:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Derek

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Human Resources

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2026		M		2,069	A	$162.6	14,531	D
Common Stock	08/06/2026		S		2,069(1)	D	$402.5444(2)	12,462	D
Common Stock	08/06/2026		M		1,821	A	$177.46	14,283	D
Common Stock	08/06/2026		S		1,821(1)	D	$402.5444(2)	12,462(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nqso (Right to Buy)	$162.6	08/06/2026		M			2,069	05/01/2019	05/02/2027	Common Stock	2,069	$0	0	D
Nqso (Right to Buy)	$177.46	08/06/2026		M			1,821	04/27/2020	04/27/2028	Common Stock	1,821	$0	0	D

Explanation of Responses:

1. Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

2. The price reported is an average price of $402.5444 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

3. These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Derek Miller	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)